---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-258568"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:23:47.921921+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aileron Therapeutics reports Q3 net loss of $5.8M; Phase 1b LTI-03 shows positive biomarker data

## Summary
- Net loss of $5.8M ($0.27 per share) compared to $1.8M ($0.40) in Q3 2023; R&D expenses increased to $3.7M from $0.1M.
- Cash and equivalents at $17.7M as of Sept 30, 2024, expected to fund operations into June 2025.
- Phase 1b high-dose LTI-03 (5mg BID) in IPF showed dose-dependent biomarker effects; combined cohort data achieved statistical significance in 4 of 8 biomarkers.
- Planning underway for Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis (IPF).
- Exclusive option agreement with Advancium Health Network for ALRN-6924 (oncology) granted; non-refundable fee received, potential milestone and royalty payments.

## SEC filing metadata
- accession: 0001193125-24-258568
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312524258568/0001193125-24-258568-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312524258568/d912402d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-258568
- JSON: https://secwatch.observer/filing/0001193125-24-258568.json
- Plain text: https://secwatch.observer/filing/0001193125-24-258568.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.